Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8630 via test inhaler · 1 trial · 1 indication
To evaluate the relative bioavailability of AZD8630 test device compared to AZD8630 Monodose device.
| Arm | Type | Description |
|---|---|---|
| Sequence 1 (Treatment A- Treatment B) | EXPERIMENTAL | Participants will receive Treatment A (AZD8630 Monodose inhalation powder) crossover to Treatment B (AZD8630 test inhalation powder) |
| Sequence 2 (Treatment B- Treatment A) | EXPERIMENTAL | Participants will receive Treatment B (AZD8630 test inhalation powder) crossover to Treatment A (AZD8630 Monodose inhalation powder) |
| Name | Type | Description |
|---|---|---|
| AZD8630 (test formulation) via test inhaler | DRUG | Participants will receive AZD8630 via test inhaler. |
| AZD8630 (reference formulation) via Monodose inhaler | DRUG | Participants will receive AZD8630 via Monodose inhaler. |
| Test inhaler | DEVICE | Participants will receive AZD8630 via test inhaler. |
| Monodose inhaler | DEVICE | Participants will receive AZD8630 via Monodose inhaler. |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures. * Healthy participants aged 18-55 years with suitable veins for cannulation or repeated venipuncture. * Females participants of childbearing potential must not be lactating and, if ...
AZD8630 is an investigational small molecule being developed by AstraZeneca PLC (AZN). It is currently in Phase 1 clinical development. A completed study, NCT06531811, investigated the relative bioavailability of AZD8630 following a device and formulation transition in healthy participants.
AZD8630 is being studied for use in healthy participants. The completed Phase 1 trial, NCT06531811, evaluated the relative bioavailability of AZD8630 following a device and formulation transition. The study enrolled 32 healthy volunteers in the United States.
AZD8630 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is an investigational small molecule currently in Phase 1 clinical development.
AZD8630 is in Phase 1 clinical development. The drug is investigational and not approved. A Phase 1 study, NCT06531811, has been completed, which evaluated the relative bioavailability of AZD8630 following a device and formulation transition in healthy participants.
AZD8630 has one completed clinical trial, NCT06531811, titled "A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants." This Phase 1 study enrolled 32 healthy participants in the United States.